Trial Profile

A randomised phase II study evaluating cediranib versus cediranib and saracatanib in patients with relapsed metastatic clear cell renal cancer.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cediranib (Primary) ; Saracatinib (Primary)
Indications Renal cell carcinoma
Focus Therapeutic Use
Acronyms COSAK

Most Recent Events

06 Jun 2017 Results of retrospective analysis assessing dynamic changes in prognostic marker to predict survival presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
22 Jan 2016 Results published in the Annals of Oncology
31 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ISRCTN.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com